Impact Biomedical Inc.

Impact Biomedical Inc. (IBO), already reporting to the SEC, moved up to NYSE American on Sep 17, 2024 with an offering at $3.00 per share raising $4.5M. Revere was lead-left underwriter.

Impact BioMedical, Inc. is a human healthcare and consumer wellness company with no significant revenue. Its Linebacker platform of modified polyphenol compounds targets solid tumors, inflammatory disorders and neurology, and it also holds Equivir antiviral polyphenol blends and a fragrance and flavor technology.

Status

Uplisting

Ticker

IBO

Exchange

NYSE American

Listed

Sep 17, 2024

Price

$3.00

Raised

$4.5M

Market cap at IPO price

$34.5M

First filed

Feb 12, 2021

Underwriters

Revere

Sector

Biotech & pharma

Country / state

NY